Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use

There is great heterogeneity in drug treatment response that is thought to be due to individual-level allelic variation in pharmacogenomic biomarkers. FDA Drug Labels provide information to guide pharmacogenomic biomarker use. Yet, the strength of evidence for clinical validity and clinical utility...

Descripción completa

Detalles Bibliográficos
Autores principales: Chin, Lauren, Devine, Beth, Baradaran, Sarah, Keyloun, Katelyn, Canestaro, William, Pham, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Informatics Association 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543369/
https://www.ncbi.nlm.nih.gov/pubmed/28815101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543369/
https://www.ncbi.nlm.nih.gov/pubmed/28815101

Ejemplares similares